This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate ...

Q1 2026 earnings call recap: margins up, cost cuts, new PlusHLTH launches, CMS BEI update & cash flow outlook—read now.

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

EPS/revenue estimates, cautious analyst views, 2026 EPS guidance, and HIV outlook to 2036—read now before May 7.

More than 140,000 fake citations across four research repositories were identified in papers and preprints published in 2025 ...

Graduates from Quinnipiac’s College of Arts & Sciences and School of Communications celebrated Commencement on Saturday at ...